Brian Skorney

Baird Analyst Says 'Don't 'Give Up' Yet On Gilead's Remdesivir

Aimmune Analyst Says Palforzia Launch Funding Secured With Nestle's $200M Investment

Aimmune Analysts Bullish On Strong Uptake Of Peanut Allergy Drug Palforzia

Aimmune Analyst Says Palforzia Launch Funding Secured With Nestle's $200M Investment

Aimmune Analysts Bullish On Strong Uptake Of Peanut Allergy Drug Palforzia

Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade

Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes

Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade

|

Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes

|

Biotech Stock On The Radar: Aimmune Awaits Adcom Test

|

Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts

|

Brian Skorney Recent News

Analysts Laud Biogen's M&A Strategy Following Deal to Buy Gene Therapy Company Nightstar

|

Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises

|

Baird: Prospects For Proteostasis Therapeutics' PTI-428 Are Not Priced Into The Stock

|

Analyst: Regeneron Is Undervalued By The Street

|

Regeneron Pharmaceuticals Gains A Bull Ahead Of Earnings

|

Pipeline Bomb: Analysts Review Celgene's Crohn's Diseases Failure

|

Celgene's Pipeline In Question After GED Failure

|

Analyst Says Axovant's Bull Case Is Effectively Over

|

FDA Letter On Intercept Pharma Doesn't Include Black Box Warning Label...Yet

|

Expectations For Regeneron No Longer Realistic; Analyst Downgrades

|

Approval For Neurocrine's Ingrezza Was No Surprise, But Lack Of Warning Label A Big Advantage Over Teva

|

The Street Is Misreading Sarepta's Guidance

|

Gilead's 2017 Guidance Sank Shares To A New Bottom

|

Theravance Biopharma's Valuation Has Gotten A Little Carried Away

|

Sarepta's Deal With Summit Could Be More About European Eteplirsen Approval Expectations

|

Patent Trial And Appeal Board Hands Sarepta Another Big Win

|

Drug Trial Extension By FDA Doesn't Change Baird's Outlook On Sarepta

|

Is Biogen Becoming A Reasonable Target For Acquisition? Baird Says So

|

Baird: Gilead Set For Q1 EPS Miss, But Hep C Trends Still Good Long Term

|

Baird And Piper Jaffray Love Vertex: Here's Why

|

All-Star Analysts Discuss GoPro, Apple & Gilead Before They Make Headlines

|

Baird Comments On Achillion's Bullish Share Action

|

VRTX Well Positioned To Capture Initial Paradigm Shift In Hep C Therapy

|